Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. JD Health International Inc.
  6. Ratings
    6618   KYG5074A1004

JD HEALTH INTERNATIONAL INC.

(6618)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Investment
Trading
ESG Refinitiv -
Financials
Sales Growth
Growth rating is based on the evolution of the turnover of the company between the last year and the three coming years according to consensus estimates
Earnings Growth
EBITDA / Sales
Profitability
Profitability rating is based on net margin of the company for the current year and the next one according to consensus estimates
Finances
Finances rating is based on the evolution of the net debt of the company (debt or cash) and its Ebitda, compared to its revenue
Valuation
P/E ratio
Price Earnings Ratio rating compared the company’s current share price to its per-share earnings for the current fiscal year and the next one
EV / Sales
Valuation rating is based on the ratio between enterprise value and its turnover for the current fiscal year and the next one
Price to Book
Price to Free Cash Flow -
Yield
"Yield" rating is based on the dividend relative to its share price
-
Momentum
Turnover review 12m
Revenue revisions (one year) rating is based on the evolution of revenue revisions of the company for the current fiscal year and the next one
Turnover review 4m
Revenue revisions (four months) rating is based on the evolution of revenue revisions of the company for the current fiscal year and the next one
Turnover review 7 days
Earnings revision 12m
EPS revisions (one year) rating is based on the evolution of EPS (earnings per share) revisions of the company for the current fiscal year and the next one
Earnings revision 4m
EPS revisions (four months) rating is based on the evolution of EPS (earnings per share) revisions of the company for the current fiscal year and the next one
Consensus
Analyst Opinion
Consensus rating is based on analyst recommendations
Potential Price Target
Potential rating is based on the average target price fixed by the consensus from Thomson Reuters
Price target revision 4m
Revision of opinion 4m
Revision of opinion 12m
Business Predictability
Analyst Coverage
Divergence of Estimates
Business Predictability rating is based on the dispersion of analysts' estimates on the evolution of the company business in the coming years (range estimates)
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Earnings quality rating is based on quality of past earnings released by the company compared to analysts' estimates
-
Technical analysis
Short Term Timing
Short Term Timing rating is defined according to the positioning of the last closed trading price, within the area between the short term support and resistance on the basis of technical analysis in daily data
Middle Term Timing
Mid-Term Timing rating is defined according to the positioning of the last closed trading price, within the area between the mid-term support and resistance on the basis of technical analysis in daily data
Long Term Timing
Long Term Timing rating is defined according to the positioning of the last closed trading price, within the area between the long term support and resistance on the basis of technical analysis in daily data
RSI
RSI rating is based on the ranking of the security in the panel studied according to the mathematical indicator RSI 14 period
Bollinger Spread
Bollinger Bands rating is based on the ranking of the security in the panel studied according to the spread of the Bollinger bands
Unusual Volumes
Abnormal Volumes rating is based on the ranking of the security in the panel studied according to volume of the last session compared to an average session
Strengths
  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 534.48 times its estimated earnings per share for the ongoing year.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company appears highly valued given the size of its balance sheet.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector Other Drug Retailers
1st jan.Capitalisation (M$)Investor Rating
JD HEALTH INTERNATIONAL INC..-32.67%46 115
WALGREENS BOOTS ALLIANCE, I..16.68%45 087
MCKESSON CORPORATION16.51%29 594
CARDINAL HEALTH, INC.10.21%16 620
HUADONG MEDICINE CO., LTD41.72%12 785
SINOPHARM GROUP CO., LTD.16.65%9 368
SHANGHAI PHARMACEUTICALS HO..1.15%8 318
WELCIA HOLDINGS CO., LTD.-6.03%6 924
DASHENLIN PHARMACEUTICAL GR..-34.62%6 342
YIFENG PHARMACY CHAIN CO., ..-28.78%6 217
MATSUMOTOKIYOSHI HOLDINGS C..14.55%4 566
JOINTOWN PHARMACEUTICAL GRO..-21.20%4 249
CLICKS GROUP LIMITED4.38%4 242
MEDIPAL HOLDINGS CORPORATIO..9.70%4 151
ZUR ROSE GROUP AG20.32%3 940
CHINA NATIONAL MEDICINES CO..-38.63%3 849
More Results